Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Artificial skin enters donor site trial:

This article was originally published in Clinica

Executive Summary

Tissue engineering company Ortec International is to begin a pivotal clinical trial of its Composite Cultured Skin (CCS) product on burn victims. The US FDA granted New York-based Ortec permission to begin trials of CCS to close donor site wounds. The new trial will involve 75 patients at 12 burn centres in the US and its primary endpoint will compare time to wound closure versus standard wound dressings, with a six-month follow up. A pilot study of eight patients showed that CCS closed wounds an average 9.5 days earlier than a control dressing (see Clinica No 853, p 25).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT078564

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel